NCT04474704View on ClinicalTrials.gov

Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia

NACompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

May 31, 2022

Conditions
Preeclampsia With Severe Features
Interventions
DEVICE

Cheetah® non-invasive cardiac monitoring system

Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))

OTHER

Standard of care

24 hours of postpartum magnesium sulfate

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER

NCT04474704 - Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia | Biotech Hunter | Biotech Hunter